Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Adalimumab was the third TNF inhibitor to be approved for psoriasis, but has been gaining momentum in the market against etanercept, owing to superior efficacy data from clinical trials (Psoriasis ...

Proinflammatory cytokines such as tumor necrosis factor (TNF) have long been known to have an important role in the pathogenesis of psoriasis, a chronic inflammatory immune-mediated disease. 1 ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or IL-23 inhibitors compared with those receiving tumor necrosis factor (TNF ...

This process leads to increased production of TNF-α by macrophages and activation of the inflammatory response. [24] Diseases such as RA, CD, psoriasis, PsA and AS present similar characteristics ...

The still-growing list reflects recent advances in precision medicine that target specific components of the inflammatory cascade that drives psoriasis, including tumor necrosis factor (TNF)-alpha ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

NEW YORK, July 31 (Praxis Press) Patients with psoriasis and psoriatic arthritis have increased concentrations of tumor necrosis factor in their skin lesions and joints. Mease and colleagues studied ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...